Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

680
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
680
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

574
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
574
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.7K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.7K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.2K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.2K
Vaccinations01:51

Vaccinations

52.2K
Overview
52.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Preparing for Tuberculosis Vaccine M72/AS01E Implementation: A Global Demand Forecast and Key Influential Factors.

Infectious diseases and therapy·2026
Same author

A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT).

Therapeutic advances in respiratory disease·2025
Same author

Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosus.

Lupus science & medicine·2025
Same author

Long-Term Kidney Outcome of Lupus Nephritis by Renal Response Status.

Kidney international reports·2024
Same author

A comparison of GOLD 2019 and 2023 recommendations to contemporaneous real-world inhaler treatment patterns for chronic obstructive pulmonary disease management in Singapore.

Journal of thoracic disease·2024
Same author

Predictors of Organ Damage in Systemic Lupus Erythematosus in the Asia Pacific Region: A Systematic Review.

Arthritis care & research·2024

Related Experiment Video

Updated: Feb 26, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.1K

Preparing for Tuberculosis Vaccine M72/AS01E Implementation: A Global Demand Forecast and Key Influential Factors.

Judith Kallenberg1, Dominique Milea2, Thomas Breuer3

  • 1GSK, Amsterdam, The Netherlands.

Infectious Diseases and Therapy
|February 25, 2026
PubMed
Summary
This summary is machine-generated.

A new tuberculosis (TB) vaccine, M72/AS01E, shows potential for global impact. Demand forecasting estimates millions of doses needed annually, highlighting the importance of early planning for TB vaccine introduction.

Keywords:
AdolescentsDemandForecastingGavi, the Vaccine AllianceGlobal healthImmunizationM72/AS01Models (theoretic)TuberculosisVaccine

More Related Videos

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.7K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

11.1K

Related Experiment Videos

Last Updated: Feb 26, 2026

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.1K
Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
06:38

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria

Published on: December 8, 2023

1.7K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

11.1K

Area of Science:

  • * Global health and infectious disease research.
  • * Vaccine development and implementation science.

Background:

  • * Tuberculosis (TB) remains a significant global health challenge, affecting millions annually and causing substantial mortality.
  • * The M72/AS01E candidate vaccine represents a novel approach to TB prevention in adolescents and adults, marking a significant advancement after a century without new TB vaccines.

Purpose of the Study:

  • * To estimate global demand for the M72/AS01E TB vaccine to ensure manufacturing capacity.
  • * To forecast vaccine demand through 2045, considering various adoption scenarios and influencing factors.

Main Methods:

  • * Development of a global demand forecasting model incorporating TB burden, funding, and country-specific adoption capabilities.
  • * Assumptions included M72/AS01E regulatory approval in 2029, with forecasts covering routine vaccination and catch-up campaigns.

Main Results:

  • * Projected demand reaching a steady state of approximately 56 million doses annually by 2036, with a decrease to 43 million after a second TB vaccine launch in 2037.
  • * Seven countries and Gavi-eligible nations are identified as major demand centers, accounting for 61% and 50% of demand, respectively.
  • * Scenario analyses indicated potential demand fluctuations of +43% to -34% based on efficacy, funding, and policy recommendations.

Conclusions:

  • * The M72/AS01E vaccine holds significant promise for reducing the global TB burden.
  • * Successful introduction necessitates proactive planning, accurate demand forecasting, and stakeholder collaboration.
  • * Continuous model refinement and early visibility on funding and policy are crucial to prevent access delays.